NDUFAB1 and neoplasm: This is clinically relevant since novel therapies (including off-the-shelf use of MAPK pathway inhibitors against ACP) are often first tested on aggressive cases, for which there are no therapeutic alternatives, and so it is recognised that responses or lack or response to these therapeutics may not be representative of their effects on less aggressive, more typical tumours.